drugset
drugset / Trial / NCT02874924

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

NCT02874924 ↗

Phase 2 Completed 34 enrolled The University of Texas Health Science Center at San Antonio
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).

Timeline

Start
2016-06
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rapamycin Small molecule 1 mg —

Indications

No indication recorded.